
09/24/2025
A new study suggests that using GLP-1 receptor agonists for obesity may significantly reduce the risk of primary open-angle glaucoma (POAG) and ocular hypertension—by over 50–60% in 3 to 5 years! While more research is needed to confirm causality, these findings highlight another potential benefit of GLP-1 medications. 🌟